A Comparative Study of High-dose Interferon Alfa-2a and Pegylated Interferon Alfa-2a for Induction Therapy in Difficult to Treat Genotype 1 Patients With Chronic HCV
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW
研究概览
简要总结
Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.
详细描述
The purpose of this study is to compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCVRNA suppression of 360 mug peginterferon QW, 9 MU interferon daily or 4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment. Comparison of virological breakthrough/relapse rate after dose adjustments and sustained virological response rate will be assessed by the type of induction.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •chronic hepatitis C
- •detectable serum HCV-RNA
- •elevated serum ALT activity documented on at least two occasions within the past 12 months, with at least one during the 90 day screening period preceding the initiation of test drug dosing
- •liver biopsy findings (during screening or within previous 12 months) consistent with active fibrosis (haemophiliacs are excluded from biopsies)
- •compensated liver disease (Child-Pugh Grade A clinical classification)
- •negative urine or blood pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of study drug
- •all fertile males and females receiving ribavirin and their fertile or potentially fertile partners must be advised to use two forms of effective contraception (combined) during treatment and during the 6 months after end of treatment
排除标准
- •history or other evidence of severe illness, malignancy or any other condition which would make the patient, in the opinion of the investigator, unsuitable for the study
- •women with ongoing pregnancy or breast feeding
- •therapy with any systemic anti-viral, anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) <3 months prior to the first dose of study drug
- •any investigational drug <6 weeks prior to the first dose of study drug positive test at screening for HBsAg, anti-HIV Ab history or other evidence of bleeding from esophageal varices, ascites, or other conditions consistent with decompensated liver disease (Child-Pugh Grade B or C clinical classification)
- •Signs or symptoms of hepatocellular carcinoma
- •history or other strong evidence of a medical condition associated with chronic liver disease other than HCV (e.g., primary hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposures
- •Hb <7.5 mmol/l in women or <8.6 mmol/l in men at screening
- •any patient with an increased baseline risk for anaemia (e.g. thalassemia, spherocytosis, etc) or for whom anaemia would be medically problematic neutrophil count <1500 cells/mm3 or platelet count <80,000 cells/mm3 at screening
- •serum creatinine level >1.5 times the upper limit of normal at screening
- •history of severe psychiatric disease, especially depression
- •history of a severe seizure disorder or current anticonvulsant use
- •history of immunologically mediated disease
- •history or other evidence of chronic pulmonary disease associated with functional limitation
- •history of severe allergies
- •history of symptomatic and/or significant cardiovascular disease
- •poorly controlled diabetes mellitus
- •history of major organ transplantation with an existing functional graft
- •hyper- or hypothyroidism
- •evidence of severe retinopathy
- •evidence of drug abuse (including excessive alcohol consumption within one year before study entry
研究组 & 干预措施
360 PEG IFN
360 mug peginterferon alfa-2a QW
干预措施: Peginterferon alfa-2a (Drug)
360 PEG IFN
360 mug peginterferon alfa-2a QW
干预措施: Ribavirin (Drug)
9 MU + 180 PEG IFN
9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Peginterferon alfa-2a (Drug)
9 MU + 180 PEG IFN
9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Interferon alfa-2a (Drug)
9 MU + 180 PEG IFN
9 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Ribavirin (Drug)
4,5 MU IFN + 180 PEG IFN
4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Peginterferon alfa-2a (Drug)
4,5 MU IFN + 180 PEG IFN
4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Interferon alfa-2a (Drug)
4,5 MU IFN + 180 PEG IFN
4,5 MU interferon daily in combination with 180 mug peginterferon QW in the first 4 weeks of treatment
干预措施: Ribavirin (Drug)
结局指标
主要结局
To compare pharmacokinetics by IFN assays and pharmacodynamics by patient's HCV RNA suppression of 360 mug peginterferon alfa-2a QW, 9 MU interferon alfa-2a daily or 4,5 interferon alfa-2a daily in combination with 180 mug peginterferon alfa-2a QW
时间窗: week 4
次要结局
- To compare the virological breakthrough/relapse rate after dose adjustments (at 4,24,72) weeks.(week 4, 24 and 72)
- To compare the sustained virological response rate at 24 weeks after end of treatment.(week 24 follow up)